The First-in-Human trial demonstrated that the novel challenge agent had high attack rates of up to 100%. (Image: iStock/bodym)

SGS completes Ph I trial of new influenza virus

By Melissa Fassbender

SGS has completed a Phase I clinical trial of a new influenza virus strain in healthy volunteers and has increased capacity at its Mississauga, Canada-based laboratory.

ABL is providing services as part of BARDA's Fill-Finish Manufacturing Network. (Image: iStock/BernardaSv)

ABL to fill live virus-based MCMs for BARDA

By Melissa Fassbender

ABL, Inc. will provide fill/finish services for live virus-based medical countermeasures (MCM) as part of the five-year contract worth up to $50m.


Follow us


View more


Featured Suppliers

All suppliers